Morgan Stanley Biogen Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Biogen Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,956,210 shares of BIIB stock, worth $283 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,956,210

Previous 1,990,668 1.73%

Holding current value

$283 Million

Previous $272 Million 9.81%

% of portfolio

0.02%

Previous 0.02%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$113.38 - $135.49 $3.91 Million - $4.67 Million	-34,458 Reduced 1.73%	1,956,210 $246 Million
Q1 2025 May 15, 2025	BUY	$133.43 - $153.27 $27.8 Million - $31.9 Million	208,312 Added 11.69%	1,990,668 $272 Million
Q4 2024 Feb 14, 2025	SELL	$146.47 - $191.55 $15.4 Million - $20.1 Million	-104,890 Reduced 5.56%	1,782,356 $273 Million
Q3 2024 May 14, 2025	BUY	$189.07 - $236.8 $53.1 Million - $66.5 Million	280,738 Added 17.48%	1,887,246 $366 Million
Q3 2024 Nov 14, 2024	BUY	$189.07 - $236.8 $53.1 Million - $66.5 Million	280,738 Added 17.48%	1,887,246 $366 Million
Q2 2024 May 14, 2025	SELL	$190.52 - $236.72 $33.5 Million - $41.6 Million	-175,848 Reduced 9.87%	1,606,508 $372 Million
Q2 2024 Oct 17, 2024	SELL	$190.52 - $236.72 $18.1 Million - $22.5 Million	-94,875 Reduced 5.58%	1,606,508 $372 Million
Q2 2024 Aug 14, 2024	SELL	$190.52 - $236.72 $18.1 Million - $22.5 Million	-94,875 Reduced 5.58%	1,606,508 $372 Million
Q1 2024 Oct 17, 2024	BUY	$212.02 - $267.71 $20.1 Million - $25.4 Million	94,875 Added 5.91%	1,701,383 $367 Million
Q1 2024 Aug 16, 2024	BUY	$212.02 - $267.71 $26.2 Million - $33.1 Million	123,606 Added 7.83%	1,701,383 $367 Million
Q1 2024 May 15, 2024	BUY	$212.02 - $267.71 $26.2 Million - $33.1 Million	123,606 Added 7.83%	1,701,383 $367 Million
Q4 2023 Aug 16, 2024	SELL	$222.59 - $267.94 $6.4 Million - $7.7 Million	-28,731 Reduced 1.79%	1,577,777 $408 Million
Q4 2023 Feb 13, 2024	BUY	$222.59 - $267.94 $18.8 Million - $22.7 Million	84,664 Added 5.67%	1,577,777 $408 Million
Q3 2023 Nov 15, 2023	BUY	$253.3 - $285.89 $15.7 Million - $17.7 Million	61,814 Added 4.32%	1,493,113 $384 Million
Q2 2023 Aug 14, 2023	BUY	$275.25 - $318.06 $34.5 Million - $39.9 Million	125,448 Added 9.61%	1,431,299 $408 Million
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $30 Million - $34.2 Million	-116,965 Reduced 8.22%	1,305,851 $363 Million
Q4 2022 Feb 14, 2023	BUY	$252.44 - $306.72 $45.4 Million - $55.2 Million	180,012 Added 14.48%	1,422,816 $394 Million
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $26.1 Million - $36 Million	-134,131 Reduced 9.74%	1,242,804 $332 Million
Q2 2022 Oct 27, 2022	BUY	$187.54 - $223.02 $79 Million - $93.9 Million	421,106 Added 44.06%	1,376,935 $281 Million
Q2 2022 Aug 15, 2022	BUY	$187.54 - $223.02 $79 Million - $93.9 Million	421,106 Added 44.06%	1,376,935 $281 Million
Q1 2022 Oct 27, 2022	SELL	$193.77 - $244.14 $81.6 Million - $103 Million	-421,106 Reduced 30.58%	955,829 $201 Million
Q1 2022 May 13, 2022	BUY	$193.77 - $244.14 $34 Million - $42.8 Million	175,349 Added 22.47%	955,829 $201 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $5.99 Million - $7.7 Million	26,765 Added 3.55%	780,480 $187 Million
Q3 2021 Nov 15, 2021	BUY	$282.99 - $369.05 $213 Million - $278 Million	753,715 New	753,715 $213 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

131M

Call Options Held

2.87M

Put Options Held

2.57M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $20.9B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account